N-Acetyl Epitalon Amidate

Overview

N-Acetyl Epitalon Amidate is a modified form of the Khavinson short peptide Epithalon (Ala-Glu-Asp-Gly), engineered with an N-terminal acetyl group and a C-terminal amide to reduce susceptibility to proteolysis by aminopeptidases and carboxypeptidases. It is offered as a research peptide and is not a clinically approved drug.

The unmodified tetrapeptide Epithalon was developed in the 1980s and 1990s in the St. Petersburg laboratory of Vladimir Khavinson, based on analysis of peptide fractions from the bovine pineal gland. Research by the Khavinson group explored Epithalon's effects on melatonin, immune function, and telomere biology in rodents and a limited set of human cohorts.

N-Acetyl Epitalon Amidate was developed as a research-stability improvement rather than a novel biological entity. The assumption in research use is that capping both termini allows the core AEDG motif to survive longer in circulation and at target tissues, while retaining the biological activity associated with the parent tetrapeptide.

Structure / Chemistry

• Parent sequence: Ala-Glu-Asp-Gly (Epithalon)
• N-terminal modification: Acetyl group on the alanine alpha-amine
• C-terminal modification: Glycine amide rather than free carboxylic acid
• Approximate molecular formula: C17H25N5O9
• Approximate molecular weight: 443 g/mol

Both modifications are common in peptide chemistry for extending half-life: acetylation prevents N-terminal aminopeptidase cleavage, and C-terminal amidation prevents carboxypeptidase degradation. The net charge and hydrophilicity are adjusted modestly but the overall character remains small, hydrophilic, and hydrophilic-skewed.

Mechanism of Action

N-Acetyl Epitalon Amidate is presumed to act through mechanisms documented for Epithalon, though fewer direct studies exist on the modified form:

• Telomerase activity modulation in cultured human somatic cells, reported in several Khavinson-group studies
• Melatonin pathway support via interaction with pineal gland signaling networks
• Epigenetic effects on gene expression patterns relevant to senescence, including a hypothesized direct DNA-binding model proposed by Khavinson
• Antioxidant and immune-modulatory effects described in rodent studies of aging and tumor incidence

The Khavinson "peptide bioregulator" model proposes that short peptides derived from organ tissues travel to those organs and enter cells where they interact directly with specific DNA sequences to regulate gene expression. This model remains controversial outside the Khavinson research tradition and is not broadly accepted in mainstream molecular biology.

Research Summary

Studies specifically using the N-acetyl amidated form are sparse in the peer-reviewed literature; most evidence is extrapolated from unmodified Epithalon.

Pharmacokinetics

Unmodified Epithalon has a plasma half-life estimated in minutes due to rapid proteolysis. N-Acetyl Epitalon Amidate is presumed to exhibit a modestly extended half-life, though published pharmacokinetic data specific to the modified compound is limited. Research-grade use typically employs subcutaneous or intranasal administration.

Distribution is broad but transient. The Khavinson bioregulator model posits tissue-specific accumulation in the pineal gland, though direct tracer studies are limited. Elimination is primarily renal after proteolytic breakdown.

Common Discussion Topics

• Relationship between Epithalon, N-Acetyl Epitalon Amidate, and other acetylated analogs
• Scientific acceptance of the Khavinson "peptide bioregulator" model
• Reproducibility of telomerase-activation findings in non-Khavinson labs
• Advantages and limitations of terminal capping for short peptides
• Distinction between cosmetic/research claims and clinical evidence

Related Compounds

• Epithalon — parent tetrapeptide
• Cerebrolysin — multi-peptide neurotrophic preparation
• Thymalin — another Khavinson peptide bioregulator
• Cartalax — Khavinson cartilage peptide
• Pinealon — related pineal short peptide

Educational information only. N-Acetyl Epitalon Amidate is a research peptide with limited independent validation. This article does not constitute medical or dosing advice.